File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians

TitleLamivudine prophylaxis in liver transplantation for hepatitis B in Asians
Authors
Lo, CMFan, STLai, CLLiu, CLYuen, MFNg, IOLWong, J
Issue Date1999
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceed
Citation
The 17th World Congress of the Transplantation Society, Montreal, QC., Canada, 12-17 July 1998. In Transplantation Proceedings, 1999, v. 31 n. 1-2, p. 535–536 How to Cite?
DOI: http://dx.doi.org/10.1016/S0041-1345(98)01542-5
AbstractOrthotopic liver transplantation (OLT) for hepatitis B (HBV) related liver disease is associated with a high risk of recurrence and graft loss. HBV infection is a prevalent cause of end-stage liver disease in Asia, but HBV recurrence following OLT in Asians is associated with a more virulent course and a poorer graft survival.1 Passive immunoprophylaxis with hepatitis B immunoglobulin (HBIG) is costly and may not be completely effective, particularly in patients who are positive for HBVDNA.2 We studied the efficacy and safety of a nucleoside analogue, lamivudine, without HBIG for prophylaxis of HBV reinfection in Asian patients undergoing OLT.
DescriptionThis journal issues entitled: Proceedings of the XVIIth World Congress of the Transplantation Society
Persistent Identifierhttp://hdl.handle.net/10722/101587
ISSN
0041-1345
2021 Impact Factor: 1.014
2020 SCImago Journal Rankings: 0.373
ISI Accession Number ID
WOS:000078960600233
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorLo, CM-
dc.contributor.authorFan, ST-
dc.contributor.authorLai, CL-
dc.contributor.authorLiu, CL-
dc.contributor.authorYuen, MF-
dc.contributor.authorNg, IOL-
dc.contributor.authorWong, J-
dc.date.accessioned2010-09-25T19:55:44Z-
dc.date.available2010-09-25T19:55:44Z-
dc.date.issued1999-
dc.identifier.citationThe 17th World Congress of the Transplantation Society, Montreal, QC., Canada, 12-17 July 1998. In Transplantation Proceedings, 1999, v. 31 n. 1-2, p. 535–536-
dc.identifier.issn0041-1345-
dc.identifier.urihttp://hdl.handle.net/10722/101587-
dc.descriptionThis journal issues entitled: Proceedings of the XVIIth World Congress of the Transplantation Society-
dc.description.abstractOrthotopic liver transplantation (OLT) for hepatitis B (HBV) related liver disease is associated with a high risk of recurrence and graft loss. HBV infection is a prevalent cause of end-stage liver disease in Asia, but HBV recurrence following OLT in Asians is associated with a more virulent course and a poorer graft survival.1 Passive immunoprophylaxis with hepatitis B immunoglobulin (HBIG) is costly and may not be completely effective, particularly in patients who are positive for HBVDNA.2 We studied the efficacy and safety of a nucleoside analogue, lamivudine, without HBIG for prophylaxis of HBV reinfection in Asian patients undergoing OLT.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceed-
dc.relation.ispartofTransplantation Proceedings-
dc.rightsPosting accepted manuscript (postprint): © 1999. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.rightsTransplantation Proceedings. Copyright © Elsevier Inc.-
dc.subject.meshAntiviral Agents - therapeutic use-
dc.subject.meshAsia-
dc.subject.meshDNA, Viral - blood-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHepatic Encephalopathy - surgery-
dc.subject.meshHepatitis B - prevention & control - surgery-
dc.subject.meshHepatitis B Surface Antigens - analysis - blood-
dc.subject.meshHepatitis B e Antigens - blood-
dc.subject.meshHepatitis B, Chronic - mortality - surgery-
dc.subject.meshHong Kong-
dc.subject.meshHumans-
dc.subject.meshLamivudine - therapeutic use-
dc.subject.meshLiver Transplantation - mortality-
dc.subject.meshRecurrence-
dc.subject.meshSurvival Rate-
dc.subject.meshTime Factors-
dc.titleLamivudine prophylaxis in liver transplantation for hepatitis B in Asians-
dc.typeConference_Paper-
dc.identifier.emailLo, CM: chungmlo@hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailLiu, CL: clliu@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailNg, IOL: iolng@hku.hk-
dc.identifier.emailWong, J: jwong@hkucc.hku.hk-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.authorityFan, ST=rp00355-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityWong, J=rp00322-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0041-1345(98)01542-5-
dc.identifier.pmid10083224-
dc.identifier.scopuseid_2-s2.0-0032986360-
dc.identifier.hkuros39758-
dc.identifier.hkuros39794-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032986360&selection=ref&src=s&origin=recordpage-
dc.identifier.volume31-
dc.identifier.issue1-2-
dc.identifier.spage535-
dc.identifier.epage536-
dc.identifier.isiWOS:000078960600233-
dc.publisher.placeUnited States-
dc.identifier.scopusauthoridLo, CM=7401771672-
dc.identifier.scopusauthoridFan, ST=7402678224-
dc.identifier.scopusauthoridLai, CL=7403086396-
dc.identifier.scopusauthoridLiu, CL=7409789712-
dc.identifier.scopusauthoridYuen, MF=7102031955-
dc.identifier.scopusauthoridNg, IO=7102753722-
dc.identifier.scopusauthoridWong, J=8049324500-
dc.customcontrol.immutablesml 170526 merged-
dc.identifier.issnl0041-1345-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats